{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:00:18Z","timestamp":1790182818658,"version":"4.1.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tuberculosis (TB) remains a global health issue. Treatment involves multiple anti-TB drugs, and pharmacokinetic variability may lead to toxicity or ineffective treatment. Therapeutic drug monitoring may help address these challenges. This study aimed to develop a rapid method to analyze anti-TB drugs in plasma, serum, and saliva.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A liquid chromatography\u2013tandem mass spectrometry (LC-MS\/MS) method was developed for simultaneous quantification of anti-TB drugs in plasma, serum, and saliva. The method was validated according to European Medicines Agency and Food and Drug Administration guidelines, assessing linearity, selectivity, carry-over, accuracy, precision, dilution integrity, matrix effect, recovery, and stability. Performance was evaluated across plasma, serum, and saliva and in an external quality control program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A method with a runtime of 1.7 minutes was developed to analyze 17 anti-TB drugs and 6 metabolites: (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      -desmethyl-)bedaquiline, clofazimine, delamanid, ethambutol, ethionamide, gatifloxacin, (acetyl-)isoniazid, (nor)levofloxacin, linezolid, moxifloxacin, pretomanid, protionamide, pyrazinamide, (desacetyl-)rifabutin, (desacetyl-)rifampicin, (desacetyl-)rifapentine, and tedizolid. The method demonstrated linearity, selectivity, and minimal carry-over. Accuracy and precision were within acceptable limits for all drugs and metabolites, with the largest biases observed for rifabutin (\u221213.5%) and rifapentine (11.6%). Most drugs were stable, although delamanid and protionamide required immediate processing. All analytes met the precision criteria (CV &lt;15%) in serum and saliva, whereas matrix-specific calibrators were required for some analytes to achieve acceptable accuracy (bias &lt;15%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This validated LC-MS\/MS method allows simultaneous analysis of multiple anti-TB drugs in plasma, serum, and saliva, facilitating clinical and research applications. The method has been successfully applied in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001532","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:00:42Z","timestamp":1790179242000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Development, Validation, and Clinical Application of a Simultaneous Quantification Method of Seventeen Antituberculosis Drugs in Plasma, Serum, or Saliva Using LC-MS\/MS"],"prefix":"10.1097","author":[{"given":"Mathieu S.","family":"Bolhuis","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin M.","family":"Jongedijk","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onno W.","family":"Akkerman","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Disease and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands;"},{"name":"Tuberculosis Center Beatrixoord, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands;"},{"name":"Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; and"},{"name":"Pharmacometrics Excellence Center of the Northern Netherlands, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3420-0591","authenticated-orcid":false,"given":"Marieke G. G.","family":"Sturkenboom","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands;"},{"name":"Pharmacometrics Excellence Center of the Northern Netherlands, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"R3-20260923","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"R4-20260923","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1093\/cid\/ciac528","article-title":"Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis","volume":"76","author":"Padmapriyadarsini","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R5-20260923","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.cct.2020.105938","article-title":"High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: study protocol for TBTC study 31\/ACTG A5349 phase 3 clinical trial","volume":"90","author":"Dorman","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"R6-20260923","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med"},{"key":"R7-20260923","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5588\/ijtld.22.0188","article-title":"Clinical standards for the dosing and management of TB drugs","volume":"26","author":"Alffenaar","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"R8-20260923","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5588\/ijtld.24.0597","article-title":"Drug management of TB in the intensive care setting: an international multicentre study","volume":"29","author":"Tiberi","year":"2025","journal-title":"Int J Tuberc Lung Dis"},{"key":"R9-20260923","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40268-024-00458-6","article-title":"Linezolid-induced thrombocytopenia in patients with renal impairment: a case series, review and dose advice","volume":"24","author":"Laarhuis","year":"2024","journal-title":"Drugs R D"},{"key":"R10-20260923","doi-asserted-by":"crossref","first-page":"772","DOI":"10.5588\/ijtld.22.0698","article-title":"Isoniazid and rifampicin exposure during treatment in drug-susceptible TB","volume":"27","author":"Akkerman","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"R11-20260923","doi-asserted-by":"crossref","first-page":"e9425","DOI":"10.1002\/rcm.9425","article-title":"A high-throughput LC-MS\/MS method for simultaneous determination of isoniazid, ethambutol and pyrazinamide in human plasma","volume":"37","author":"Pr\u0161o","year":"2023","journal-title":"Rapid Commun Mass Spectrom"},{"key":"R12-20260923","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpba.2014.09.019","article-title":"Development and validation of liquid chromatography tandem mass spectrometry method for simultaneous quantification of first line tuberculosis drugs and metabolites in human plasma and its application in clinical study","volume":"102","author":"Hee","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"R13-20260923","doi-asserted-by":"crossref","first-page":"89","DOI":"10.17145\/jab.15.015","article-title":"Quantification of isoniazid, pyrazinamide and ethambutol in serum using liquid chromatography-tandem mass spectrometry","volume":"1","author":"Sturkenboom","year":"2015","journal-title":"J Appl Bioanal"},{"key":"R14-20260923","doi-asserted-by":"crossref","first-page":"122986","DOI":"10.1016\/j.jchromb.2021.122986","article-title":"LC-MS\/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: implications for therapeutic drug monitoring","volume":"1185","author":"Kivrane","year":"2021","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R15-20260923","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.tube.2017.11.012","article-title":"Rapid and sensitive method for simultaneous determination of first-line anti-tuberculosis drugs in human plasma by HPLC-MS\/MS: application to therapeutic drug monitoring","volume":"109","author":"Gao","year":"2018","journal-title":"Tuberculosis"},{"key":"R16-20260923","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1039\/D0AY00889C","article-title":"A simple and reliable analytical method for simultaneous quantification of first line antitubercular drugs in human plasma by LCMS\/MS","volume":"12","author":"Panda","year":"2020","journal-title":"Anal Methods"},{"key":"R17-20260923","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/jac\/dkt154","article-title":"Method for simultaneous analysis of nine second-line anti-tuberculosis drugs using UPLC-MS\/MS","volume":"68","author":"Han","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R18-20260923","doi-asserted-by":"crossref","first-page":"124470","DOI":"10.1016\/j.jchromb.2025.124470","article-title":"Development and validation of an LC-MS\/MS multiplex assay for the quantification of bedaquiline, n-desmethyl bedaquiline, linezolid, levofloxacin, and clofazimine in dried blood spots","volume":"1252","author":"Kenfack Teponnou","year":"2025","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R19-20260923","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jchromb.2015.11.058","article-title":"Development and validation of LC-ESI-MS\/MS method for analysis of moxifloxacin and levofloxacin in serum of multidrug-resistant tuberculosis patients: potential application as therapeutic drug monitoring tool in medical diagnosis","volume":"1009-1010","author":"Lee","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R20-20260923","doi-asserted-by":"crossref","first-page":"122397","DOI":"10.1016\/j.jchromb.2020.122397","article-title":"Development and validation of a simple LC-MS\/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma","volume":"1158","author":"Zheng","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R21-20260923","doi-asserted-by":"crossref","first-page":"122141","DOI":"10.1016\/j.jchromb.2020.122141","article-title":"Validation of a universal and highly sensitive two-dimensional liquid chromatography\u2013tandem mass spectrometry methodology for the quantification of pyrazinamide, ethambutol, protionamide, and clofazimine in different biological matrices","volume":"1151","author":"Wu","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R22-20260923","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpba.2014.08.026","article-title":"Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry","volume":"102","author":"Kim","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"R23-20260923","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.3390\/pharmaceutics15112543","article-title":"A single-run HPLC\u2013MS multiplex assay for therapeutic drug monitoring of relevant First- and second-line antibiotics in the treatment of drug-resistant tuberculosis","volume":"15","author":"K\u00f6hler","year":"2023","journal-title":"Pharmaceutics"},{"key":"R24-20260923","doi-asserted-by":"crossref","first-page":"e8667","DOI":"10.1002\/rcm.8667","article-title":"Simple and sensitive method for the analysis of 14 antituberculosis drugs using liquid chromatography\/tandem mass spectrometry in human plasma","volume":"34","author":"Lei","year":"2020","journal-title":"Rapid Commun Mass Spectrom"},{"key":"R26-20260923","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"R27-20260923","first-page":"1","article-title":"ICH Guideline M10 on bioanalytical method validation and study sample analysis","volume":"44","year":"2022","journal-title":"EMA Sci Medicines Health"},{"key":"R28-20260923","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/jac\/dkae105","article-title":"Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations","volume":"79","author":"Stemkens","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R29-20260923","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1128\/AAC.00276-15","article-title":"Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry","volume":"59","author":"Alffenaar","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-20260923","doi-asserted-by":"crossref","first-page":"e0000322","DOI":"10.1128\/aac.00003-22","article-title":"Population pharmacokinetic modelling and limited sampling strategies for therapeutic drug monitoring of pyrazinamide in patients with tuberculosis","volume":"66","author":"Abolhassani-Chimeh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20260923","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1128\/AAC.00274-11","article-title":"Population pharmacokinetics of ethambutol in South African tuberculosis patients","volume":"55","author":"J\u00f6nsson","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R32-20260923","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.4155\/bio.14.191","article-title":"Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS\/MS method","volume":"6","author":"Dijkstra","year":"2014","journal-title":"Bioanalysis"},{"key":"R33-20260923","doi-asserted-by":"crossref","first-page":"e02379-18","DOI":"10.1128\/AAC.02379-18","article-title":"Evaluation of saliva as a potential alternative sampling matrix for therapeutic drug monitoring of levofloxacin in patients with multidrug-resistant tuberculosis","volume":"63","author":"Ghimire","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R34-20260923","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jat\/34.3.135","article-title":"Determination of moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatography-tandem mass spectrometry method","volume":"34","author":"Pranger","year":"2010","journal-title":"J Anal Toxicol"},{"key":"R35-20260923","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jchromb.2009.04.038","article-title":"Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry","volume":"877","author":"de Velde","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R36-20260923","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12879-020-05738-5","article-title":"Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting","volume":"21","author":"Metcalfe","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R37-20260923","doi-asserted-by":"crossref","first-page":"107231","DOI":"10.1016\/j.ijantimicag.2024.107231","article-title":"Measurement of isoniazid in tuberculosis patients using finger sweat with creatinine normalisation: a controlled administration study","volume":"64","author":"Longman","year":"2024","journal-title":"Int J Antimicrob Agents"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:00:48Z","timestamp":1790179248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001532","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"2026-06-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}